Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Roger H, Kobayashi"'
Autor:
Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/40b30801152944dcaa8a5c8a21430349
Autor:
Sudhir, Gupta, Roger H, Kobayashi, Jiří, Litzman, Laurel, Cherwin, Sonja, Hoeller, Huub, Kreuwel
Publikováno v:
Expert Review of Clinical Immunology. 19:7-17
Human immunoglobulin (IG) administered intravenously (IVIG) or subcutaneously (SCIG) is used to prevent infections in patients with primary immunodeficiency diseases (PIDDs) such as primary antibody immunodeficiencies.This review provides an overview
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3564d3b9617ecd2b5b95c19390032de9
https://doi.org/10.1080/1744666x.2023.2144836
https://doi.org/10.1080/1744666x.2023.2144836
Autor:
Roger H, Kobayashi, Jiří, Litzman, Isaac, Melamed, J Fernando, Mandujano, Ai Lan, Kobayashi, Bruce, Ritchie, Bob, Geng, T Prescott, Atkinson, Syed, Rehman, Sonja, Höller, Eva, Turpel-Kantor, Huub, Kreuwel, J C, Speer, Sudhir, Gupta
Publikováno v:
Clinical and Experimental Immunology. 210:91-103
A prospective study and its long-term extension examined whether weekly treatment of patients with primary immunodeficiencies (PIDs) with a 16.5% subcutaneous immunoglobulin (SCIg; cutaquig®) confers acceptable efficacy, safety, and tolerability ove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b5ba846a028013e90b729c894cda558
https://doi.org/10.1093/cei/uxac092
https://doi.org/10.1093/cei/uxac092
Autor:
Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by
Externí odkaz:
https://doaj.org/article/4a2371e134b249bd837c68f3a41d8a8b
Autor:
Sudhir Gupta, James DeAngelo, Isaac Melamed, Jolan E. Walter, Ai-Lan Kobayashi, Tracy Bridges, J. Wesley Sublett, Jonathan A. Bernstein, Alan Koterba, Michael Manning, Joanna Maltese, Sonja Hoeller, Eva Turpel-Kantor, Huub Kreuwel, Roger H. Kobayashi
Publikováno v:
Journal of Clinical Immunology.
Purpose To achieve reductions in infusion time, infusion sites, and frequency, a prospective, open-label, multicenter, Phase 3 study evaluated the safety, efficacy, and tolerability of subcutaneous immunoglobulin (SCIG) 16.5% (Cutaquig®, Octapharma)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e032fde4f9e7c9f51febd51147c3e6d1
https://doi.org/10.1007/s10875-023-01509-4
https://doi.org/10.1007/s10875-023-01509-4
Autor:
Roger H, Kobayashi, Michael T, Rigas
Publikováno v:
American Journal of Health-System Pharmacy. 79:1415-1423
Purpose This report calls attention to the potential risks of diminished kidney function when administering immune globulin (IG). The goal is to increase awareness of chronic kidney disease (CKD) and kidney function impairment in patients receiving I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba18a8d4971870041fdeec7beafa30a
https://doi.org/10.1093/ajhp/zxac139
https://doi.org/10.1093/ajhp/zxac139
Autor:
Gesmar R. S. Segundo, Anh T. V. Nguyen, Huyen T. Thuc, Le N. Q. Nguyen, Roger H. Kobayashi, Hai T. Le, Huong T. M. Le, Troy R. Torgerson, Hans D. Ochs
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
BackgroundNew sequencing techniques have revolutionized the identification of the molecular basis of primary immunodeficiency disorders (PID) not only by establishing a gene-based diagnosis but also by facilitating defect-specific treatment strategie
Externí odkaz:
https://doaj.org/article/52abea3498c04200a1bc016080991b82
Autor:
Andrew Schechterman, Maeve O’Connor, Nazia Rashid, Holly Miranda, Isaac Melamed, Melinda Heffron, Roger H. Kobayashi, Sharon Canterberry, Ai Lan Kobayashi
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinical diagnosis in children who have an acute manifestation of varied neuropsychiatric symptoms, including obsessive compulsive disorder, eating disorders, tics, anxiety, irri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f9d0b24d96e53066d21a36a17a3da2
https://doi.org/10.1089/cap.2020.0100
https://doi.org/10.1089/cap.2020.0100
Publikováno v:
Immunotherapy. 14(4)
Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd89ce8dfdeb49d884cdd44c740089d1
https://pubmed.ncbi.nlm.nih.gov/34986666
https://pubmed.ncbi.nlm.nih.gov/34986666
Autor:
Manish J, Butte, Roger H, Kobayashi
Publikováno v:
The journal of allergy and clinical immunology. In practice, vol 10, iss 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70483babe0ef3b57058a4ef8f709e01d
https://doi.org/10.1016/j.jaip.2022.01.024
https://doi.org/10.1016/j.jaip.2022.01.024